Quality initiatives don't make hospitals safer

Participating in a national quality improvement initiative doesn't make a hospital any safer than those organizations not participating in such programs.

A team of researchers from the University of Michigan Medical School compared the performance of 263 hospitals participating in the American College of Surgeons' National Surgical Quality Improvement Program (ACS-NSQIP) with that of 526 hospitals not involved in the initiative for a study published in the Journal of the American Medical Association.

The study included data from more than 1.2 million Medicare beneficiaries who had undergone one of 11 major operations at the hospitals over a 10-year period.

Under the ACS-NSQIP effort, nurses at participating hospitals record and send to a secure database information on every operation performed at the facilities. ACS-NSQIP then shares quality reports so that hospitals and doctors can see how they compare with other providers.

The researchers found no indication that ACS-NSQIP hospitals performed better than non-participating hospitals.

Participating hospitals saw slight improvements in four areas, but the researchers said that the changes were not statistically significant--12.8 percent of Medicare beneficiaries were readmitted within 30 days before the hospitals enrolled in the program, compared with 13.3 percent after three years of participation; 11 percent of Medicare beneficiaries suffered serious complications before hospitals enrolled, compared with 11.1 percent after three years of participation; 4.5 percent of Medicare beneficiaries died within 30 days before hospitals enrolled, compared with 4.3 percent after three years of participation; and 0.45 percent of Medicare beneficiaries had a second operation before hospitals enrolled, compared with 0.49 percent after three years of participation.

Rates for such adverse events were slightly higher at hospitals that never participated in the program. For example, about 5% of Medicare beneficiaries at non-participating hospitals died within 30 days of their operation. However, rates also dropped at non-participating hospitals over the study period.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.